Effectiveness and safety of CT-guided percutaneous radiofrequency ablation of adrenal metastases

• Published in: British journal of radiology 2018-05, Vol.91 (1085), p.20170607-20170607
• Main Authors: Zhou, Kang, Pan, Jie, Yang, Ning, Shi, Hai-Feng, Cao, Jian, Li, Yu-Mei, Zhang, Hong-Zhi, Wang, Ke-Fei, Chen, Shao-Hui
• Format: Article
• Language: English
• Subjects: Adrenal Gland Neoplasms - diagnostic imaging; Adrenal Gland Neoplasms - secondary; Adrenal Gland Neoplasms - surgery; Adrenal Glands - diagnostic imaging; Adrenal Glands - surgery; Adrenals; Adult; Aged; Catheter Ablation - adverse effects; Catheter Ablation - methods; Diagnostic Radiology; Female; Humans; Interventional radiology; Male; Middle Aged; Radiography, Interventional - methods; Retrospective Studies; Tomography, X-Ray Computed - methods; Treatment Outcome
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.20170607

The imaging-guided percutaneous radiofrequency (RF) ablation of adrenal metastases is a relatively new treatment procedure, compared to the more widespread application of the technique for the treatment of liver and renal cancers. The present study aims to evaluate the safety and efficacy of the CT-guided percutaneous RF ablation of adrenal metastases in a cohort of patients. 33 patients with 38 adrenal metastases who received percutaneous CT-guided RF ablation between 2012 to 2015 were retrospectively reviewed. The average diameter of the treated adrenal metastases was 3.0 ± 1.6 cm. The treatment outcomes, including presence of residual tumours, technical success rate, recurrence rate, and complications, were evaluated. Patients were followed up for every 3 months to monitor the progression of the disease. Postoperative CT images showed the lack of tumour enhancement in 30 tumours (30/38 tumours, technical success rate = 78.9%), and residual disease was found in 7 tumours (7/37 tumours, 18.9%). The rate of residual disease was significantly lower in the group with tumour size